Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 2716 AL 2730

New tools for the study of Alzheimer's disease: what are biomarkers and morphometric markers teaching us?

Fjell AM, Walhovd KB.

Neuroscientist. 2011 Oct;17(5):592-605. doi: 10.1177/1073858410392586. Epub 2011 Apr 25.

Looking into posterior cortical atrophy: providing insight into Alzheimer disease

Tang-Wai DF, Graff-Radford NR.

Neurology. 2011 May 24;76(21):1778-9. doi: 10.1212/WNL.0b013e31821ccd4f. Epub 2011 Apr 27.

The three stages of Alzheimer's disease

Lancet. 2011 Apr 30;377(9776):1465. doi: 10.1016/S0140-6736(11)60582-5.

The dynamic marker hypothesis of Alzheimer's disease and its implications for clinical imaging

Cavedo E, Frisoni GB.

Q J Nucl Med Mol Imaging. 2011 Jun;55(3):237-49.

Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease

Scheinin NM, Scheinin M, Rinne JO.

Q J Nucl Med Mol Imaging. 2011 Jun;55(3):265-79.

Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls

Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S, Meyer PM, Wolf H, Zimmermann T, Reischl J, Rohde B, Gertz HJ, Reininger C, Sabri O.

Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1702-14. doi: 10.1007/s00259-011-1821-1. Epub 2011 May 6.

Biomarkers in Alzheimer's disease drug development

Cummings JL.

Alzheimers Dement. 2011 May;7(3):e13-44. doi: 10.1016/j.jalz.2010.06.004. Epub 2011 May 6.

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology

Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM.

Arch Neurol. 2011 Sep;68(9):1137-44. doi: 10.1001/archneurol.2011.105. Epub 2011 May 9.

Current strategies in the discovery of small-molecule biomarkers for Alzheimer's disease

Whiley L, Legido-Quigley C.

Bioanalysis. 2011 May;3(10):1121-42. doi: 10.4155/bio.11.62.

Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression

Teipel SJ, Buchert R, Thome J, Hampel H, Pahnke J.

Prog Neurobiol. 2011 Dec;95(4):547-56. doi: 10.1016/j.pneurobio.2011.05.004. Epub 2011 May 12.

Molecular targets in the rational design of AD specific PET tracers: tau or amyloid aggregates?

Rojo LE, Gaspar PA, Maccioni RB.

Curr Alzheimer Res. 2011 Sep;8(6):652-8. doi: 10.2174/156720511796717203.

The concept of FDG-PET endophenotype in Alzheimer's disease

During EH, Osorio RS, Elahi FM, Mosconi L, de Leon MJ.

Neurol Sci. 2011 Aug;32(4):559-69. doi: 10.1007/s10072-011-0633-1. Epub 2011 Jun 1.

Gene expression profiling of peripheral blood leukocytes identifies and validates ABCB1 as a novel biomarker for Alzheimer's disease

Chen KD, Chang PT, Ping YH, Lee HC, Yeh CW, Wang PN.

Neurobiol Dis. 2011 Sep;43(3):698-705. doi: 10.1016/j.nbd.2011.05.023. Epub 2011 Jun 6.

Treat Alzheimer disease before it is symptomatic

Rosenberg RN.

Arch Neurol. 2011 Oct;68(10):1237-8. doi: 10.1001/archneurol.2011.135. Epub 2011 Jun 13.

Biomarkers and gene mutations as aids for detecting AD early

Grandy JK.

JAAPA. 2011 Jun;24(6):56-7. doi: 10.1097/01720610-201106000-00011.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias